Accumulating evidence suggests that pharmacological manipulation of LPCAT3 activity might provide novel therapeutic methods with respect to the pathological state of atherosclerosis, non‐alcoholic steatohepatitis, carcinoma, and immuno‐ and inflammatory disorders, etc. 16. This evidence concerns the gene LPCAT3 and metabolic dysfunction-associated steatohepatitis.